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Objective: To determine the age specific serum anti-Müllerian hormone (AMH) reference values in Korean women with regular menstruation.
Methods: Between May, 2010 and January, 2011, the serum AMH levels were evaluated in a total of 1,298 women who have regular menstrual 
cycles aged between 20 and 50 years. Women were classified into 6 categories by age: 20-31 years, 32-34 years, 35-37 years, 38-40 years, 41-43 
years, above 43 years. Measurement of serum AMH was measured by commercial enzyme-linked immunoassay. 
Results: The serum AMH levels correlated negatively with age. The median AMH level of each age group was 4.20 ng/mL, 3.70 ng/mL, 2.60 ng/
mL, 1.50 ng/mL, 1.30 ng/mL, and 0.60 ng/mL, respectively. The AMH values in the lower 5th percentile of each age group were 1.19 ng/mL, 
0.60 ng/mL, 0.42 ng/mL, 0.27 ng/mL, 0.14 ng/mL, and 0.10 ng/mL, respectively.
Conclusion: This study determined reference values of serum AMH in Korean women with regular menstruation. These values can be applied 
to clinical evaluation and treatment of infertile women.  
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Introduction 
Assessment of ovarian reserve has been an important issue in infer-
tility and assisted reproductive technololy [1,2]. Ovarian reserve tests 
include serologic markers and ultrasonographic markers, such as an-
tral follicle count (AFC) and ovarian volume. Basal FSH, estrogen, and 
inhibin B have been commonly measured by serologic tests, but have 
several limitations in that it is difficult to predict hyperresponders and 
poor responders and they shoud be measured during menstrual pe-
riods [1-4]. 
Recently, serum anti-Müllerian hormone (AMH) has emerged as a 
novel marker for ovarian function [5-9]. AMH is a member of the 
transforming growth factor-beta superfamily and is expressed in the 
growing preantral or small antral follicles in the ovary, but is not ex-
pressed in ovulatory, atretic follicles, and theca cells. Serum AMH 
concentrations show little inter- and intra-cycle variability and reflect 
the recruited ovarian follicular pool [7]. Currently, serum AMH level is 
often measured during an initial work-up for infertility at several fer-
tility centers in Korea. However, there are no age-related reference 
values for AMH levels based upon a large Korean population. The 
aim of this study was to establish reference values for AMH in Korean 
women with regular menstrual cycles.
Methods
1. Study population
All individual patients’ serum AMH levels were measured between 
May, 2010, and January, 2011, in Cheil General Hospital and Women’s 
Health Care Center, Seoul, Korea. This study population included a 
total of 1,298 women who had regular menstrual cycles (interval 21-
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35 days) aged between 20 and 50 years. Exclusion criteria consisted 
of the following factors: 1) Polycystic ovary syndrome (PCOS), 2) Pre-
vious history of ovarian surgery (including oophorectomy and enu-
cleation of ovarian cysts), 3) body mass index≥30 kg/m², 4) other 
endocrine disease (thyroid disease, diabetes mellitus, Cushing’s syn-
drome). This study population was divided to six age groups: 20-31 
years, 32-34 years, 35-37 years, 38-40 years, 41-43 years, and over 43 
years. 
The study was approved by the Institutional Review Board of Cheil 
General Hospital.
2. AMH assay
On day 2-3 of a spontaneous menstrual cycle, the blood samples 
for the assay of FSH and AMH were obtained by venipuncture. The 
serum AMH levels were measured by enzyme immunoassay using 
an AMH/MIS EIA kit, which is a two-immunological step sandwich 
type assay (Immunotech version; Beckman Coulter, Marseille, France). 
First, the hormone was captured by a monoclonal antibody bound 
to the microtiter plate. Then, another monoclonal antibody with 
streptavidin-peroxidase bound to the solid phase antibody-antigen 
complex. After incubation, the antibody-antigen complex was de-
tected by addition of a chromogenic substrate. The serum AMH con-
centration was presented by intensity of the coloration in the blood 
samples and then converted to ng/mL (conversion factor to pmol/
L=ng/mL×7.14). The measurement range of the assay was from 
0.14 ng/mL to 21 ng/mL. Serum AMH values below the reported 
clinical level of measurement (0.14 ng/mL) were treated as a zero 
value for analysis. The intra- and interassay coefficients of variation 
were 12.3% and 14.2%, respectively.
3. Statistical analysis
Statistical analysis was performed using SPSS ver. 12.0 (SPSS, Chica-
go, IL, USA). To determine the correlation between AMH and other 
variables, the data was analyzed by Pearson’s correlation. Regression 
analysis was performed to present the age-related changes in AMH 
and FSH. Comparisons between age groups were performed using 
one-way analysis of variance. Each variable was presented as mean± 
SD. p<0.05 was considered statistically significant.
Results
The mean age of the 1,298 women was 34.4±0.1 years, and the 
mean AMH level was 3.6±0.1 ng/mL. The mean level of serum FSH 
and estradiol were 8.9±0.2 mIU/mL and 35.0±1.4 pg/mL, respec-
tively. Serum AMH was correlated with age (rp =-0.417, p<0.001) 
and FSH (rp =0.328, p<0.001), but was not correlated with other 
variables. Figure 1 shows a continuous regression between AMH val-
ue and age (R
2=0.183, p<0.001) and FSH value and age (R²=0.077, 
p<0.001). Approximately 75% of women (978/1,298) showed a se-
rum AMH level below 5.0 ng/mL (Figure 2). 
Women were classified into 3 categories by age: 20-29 years, 30-39 
years, 40-50 years. There are significant differences in mean and me-
dian serum AMH (5.46±2.23 vs. 3.74±2.89 vs. 1.47±1.59 ng/mL, 
p<0.001) and serum FSH (6.73±2.30 vs. 8.47±6.45 vs. 12.58±8.91 
mIU/mL, p<0.001)of each age groups. To present the age-specific 
AMH levels associated ovarian reserves, women were subdivided 
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Figure 1. Age-specific anti-Müllerian hormone (AMH) and FSH concentrations. www.eCERM.org
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Figure 2. Distribution of serum anti-Müllerian hormone (AMH) con-
centrations in women with regular menstruation.
Table 1. Basal characteristics of each age group with regular menstruation
Age (yr)
20-31 32-34 35-37 38-40 41-43 ≥44
Cases (n) 377 331 283 173 87 47
Age (yr) 29.1±0.1 33.1±0.4 35.9±0.5 39.0±0.6 41.7±0.1 45.6±0.3
Body mass index (kg/m²) 20.1±0.1 20.5±0.1 21.0±0.2 21.1±0.2 21.4±0.3 22.2±0.5
Basal FSH (mIU/mL) 7.3±0.2 7.7±0.2 9.4±0.7 9.9±0.4 12.1±1.0 15.9±1.8
Basal E2 (pg/mL) 36.1±3.0 34.0±1.5 33.7±3.8 37.2±3.7 31.8±3.3 38.7±10.3
TSH (μU/mL) 2.3±0.1 2.3±0.1 2.4±0.1 2.2±0.1 2.3±0.2 2.5±0.3
Prolactin (ng/mL) 15.8±0.8 15.0±0.7 15.0±0.6 15.4±0.8 12.1±0.7 15.0±2.3
The values are expressed as means±SD. 
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Figure 3. Serum anti-Müllerian hormone (AMH)  concentration of the 
age group. Values are median (Lines), 25-75th percentiles (boxes) and 
95% confidence interval (whiskers).
Table 2. The serum AMH levels of the age group with regular menstruation
Age (yr)
20-31 32-34 35-37 38-40 41-43 ≥44
AMH (ng/mL) 4.94±0.17
a 4.25±0.17
a 3.22±0.15
a 2.13±0.15
a 1.47±0.13
a 0.95±0.14
a
(95% CI) (4.61-5.26) (3.92-4.57) (2.92-3.51) (1.83-2.44) (1.21-1.71) (0.68-1.23)
Percentile 
5th 1.19 0.60 0.42 0.27 0.14 0.10
10th 1.60 1.10 0.70 0.50 0.30 0.10
25th 2.50 2.00 1.20 0.80 0.60 0.40
50th 4.20 3.70 2.60 1.50 1.30 0.60
75th 6.65 5.70 4.40 2.60 2.00 1.30
90th 9.30 8.30 6.40 4.42 2.92 2.24
95th 11.41 10.70 8.18 6.82 3.82 3.26
AMH, anti-Müllerian hormone; CI, confidence interval.
aThe values are expressed as means±SD.  doi: 10.5653/cerm.2011.38.2.93
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into the following groups on the basis of their ages: 20-31 years (n= 
377); 32-34 years (n=331); 35-37 years (n=283); 38-40 years (n=173); 
41-43 years (n=87); >43 years (n=47). The basal characteristics of 
each age group are described in Table 1. Both median and mean 
AMH levels of each age group decreased steadily with increasing age 
(Table 2). Figure 3 shows the median, 95% confidence intervals, and 
25-75th percentiles calculated for each age group. The AMH values in 
the lower 5th percentiles of each age group were 1.19 ng/mL, 0.60 
ng/mL, 0.42 ng/mL, 0.27 ng/mL, 0.14 ng/mL, and 0.10 ng/mL, in or-
der from the youngest to oldest groups. Figure 4 shows also age-re-
lated nomogram of serum AMH concentrations.
Discussion
A large number of studies have decribed the correlation of serum 
AMH levels with age. This hormone appears in the 36th week of ges-
tation and decreases continuously through puberty. It becomes un-
detectable when menopause occurs [10,11]. Serum AMH is produc-
ed by granulosa cells from the preantral and small antral follicles. 
Several studies have demonstrated that AMH inhibits primordial fol-
licle recruitment and also decreases the responsiveness of growing 
follicles to FSH. Thus, serum AMH levels are considered to reflect the 
number of small growing follicles, and are reduced through repro-
ductive life. Accordingly, many studies have suggested that the se-
rum AMH could be a novel ovarian reserve test. 
La Marca et al. [12] showed that serum AMH levels, unlike other 
ovarian reserve tests, do not change significantly throughout the 
menstrual cycle. Other studies have also confirmed that the intercy-
cle and intracycle variability of serum AMH levels is very low enough, 
in fact, to allow random timing of AMH measurement during the 
menstrual cycle. Hence, it has been suggested that AMH values are 
more convenient and more effective than other serum ovarian re-
serve tests like FSH and inhibin B or estradiol.
However, few studies reported on normal reference levels for se-
rum AMH values. Recently, Seifer et al. [8] have examined age-specif-
ic serum AMH values for 17,120 women of reproductive age from 24 
to 50 years old presenting to fertility centers within the United States. 
The study showed that the serum AMH levels decreased steadily with 
increasing age. However, the results of that study derived from the 
serum AMH levels of women during fertility evaluation, and thus 
were not representative of the general population. In that study, the 
age-specific mean and median values were somewhat lower (both 
1.0 ng/mL) than our study. Another study performed in the United 
States reported age-specific reference values of AMH examined in 
792 infertile women within five age groups [13]. More than half in 
that study population had diminished ovarian reserves and prema-
ture ovarian failure. Therefore, that study presented lower median 
AMH values than our study. In Italy, La Marca et al. [7] evaluated a co-
hort of 277 women that had regular menstruation patterns: they ex-
cluded women affected by confounding factors such as PCOS or a 
history of ovarian surgery. Those within a given age group in that 
study had similar median AMH levels, like our study. 
This is the largest study to present serum AMH reference values in 
Korean women with normal mensturation patterns between 20 and 
50 years old. We excluded women who had a history of ovarian sur-
gery and PCOS. We found that serum AMH levels decline with increa-
sing age, and approximately 75% of women showed a serum AMH 
value below 5 ng/mL. To present age-specific serum AMH levels, the 
study population was divided to six age groups. The median and the 
mean AMH levels in the 32- to 34-year-old, 35- to 37-year-old, 38- to 
40-year-old age groups may be especially useful in determining fer-
tility treatment options [5]. In addition, women who have AMH levels 
below the 5th percentiles of their own age group may need consul-
tation on more aggressive fertility treatment options.
In assisted reproductive technology, several studies have demon-
strated that serum AMH levels accurately reflect the total developing 
follicular cohort, and predict ovarian response to controlled ovarian 
stimulation. In addition, there have been many studies demonstrat-
ing that serum AMH is a better marker in predicting the number of 
retrieved oocytes than the other serum markers. A prospective study 
comparing serum AMH with AFC in 130 controlled ovarian hyper-
stimulation (COH) cycles showed that the two markers performed 
similarly in the prediction of the number of retrieved oocytes [14]. A 
few studies found AMH to be superior to AFC, whereas two studies 
produced the opposite result. Hence, it is a still a matter of debate 
whether AMH is a more accurate predictive marker compared to AFC 
in predicting ovarian response to COH. However, AMH appears to be 
the best predictive marker because it can be measured independent 
of the menstrual cycle.
Serum AMH testing may also be performed as a preoperative and 
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Figure 4. Age-related nomogram of serum anti-Müllerian hormone 
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postoperative evaluation of ovarian surgery in younger women. A 
prospective study presented the impact of laparoscopic cystectomy 
on ovarian reserve by investigating the serial changes in serum AMH 
levels after operation [15]. It was suggested that serum AMH is a use-
ful marker of ovarian reserve after ovarian surgery. Measuring serum 
AMH after ovarian surgery could be helpful in considering fertility 
treatment options. Also, serum AMH as preoperative evaluation of 
ovarian surgery may allow for clinical use to predict iatrogenic pre-
mature ovarian failure and consider the range of operation. 
In conclusion, this is the largest study to document age-specific 
AMH values for Korean women. Our results will be helpful to perform 
the evaluation of a women’s ovarian reserve, prediction of meno-
pause and iatrogenic premature ovarian failure. Also, the AMH levels 
presented in the current study may be applied to performing clinical 
evaluation of fertility and considering treatment options. Further-
more, these results will be helpful in discussions of treatment options 
for infertility between infertile couples and clinicians. In assisted re-
productive technology, having this data will be useful in predicting 
the number of retrieved oocytes for COH and ovarian hyperstimula-
tion syndrome, which is a complication of COH. More studies with re-
gards the serum AMH should be performed to extend its application 
in variable fields of female reproductive health.
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